Sentence examples for mutation assessment of from inspiring English sources

Having identified an excellent candidate mutation, assessment of respiratory chain complex assembly by one-dimensional BN-PAGE revealed a marked decrease in fully assembled Complex II, whilst levels of fully assembled complexes I, III, IV and V were comparable to controls (Fig.  3a).

Thus, if intra-patient melanoma BRAF heterogeneity exists and treatment decisions are made on the basis of mutation assessment of a single tumour, potentially effective treatment may not be offered in a significant proportion of patients, or alternatively, treatment may be administered that is potentially detrimental.

Although there are many reasons for this, it is possible that the limited sensitivity of conventional dideoxy sequencing-based methods of mutation assessment may fail to detect low-abundance oncogene mutations.

The results highlight the need for development of mutation assessment pipelines that go beyond these algorithms, particularly when evaluating homozygous nsSNPs of non-Caucasian genomes.

The new mechanism will undoubtedly reset the traditional way of mutation assessment and interpretation.

As FFPE tissues are the most common clinical specimens available for mutation analysis, assessment of the analytical sensitivity of the KRAS HRM assay was performed with patient FFPE-derived DNA instead of control cell lines bearing known KRAS mutations.

The implication of a germline polymorphism as opposed to a somatic mutation for assessment of metastasis risk is that risk assessment can be done using any tissue at the time of diagnosis or even before diagnosis of a primary tumor [ 24].

A variety of PCR methods, increasingly real time PCR (Q-PCR) targeted mutation detection assays, are currently applied for diagnostic KRAS mutation assessments [20], [21], some of which have already acquired the license for in vitro diagnostic (IVD) use in Europe [22].

This will aid the interpretation of mutations through assessment of their function at the RNA level.

There are several problems in using this technique for p53 that relate to a failure to detect all mutations plus assessment of what is positive (Hall and McCluggage, 2006) so the available evidence would favour the use of mutational analysis (Bergh et al, 1995; Aas et al, 1996; Berns et al, 2000).

This means that IHC analysis of TP53 protein accumulation is a poor predictor of TP53 mutations, and accurate assessment of TP53 mutations requires DNA analyses.